Royce & Associates LP Grows Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Royce & Associates LP grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 240.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 278,188 shares of the company’s stock after acquiring an additional 196,430 shares during the period. Royce & Associates LP’s holdings in Harmony Biosciences were worth $10,410,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in shares of Harmony Biosciences by 6.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,691,581 shares of the company’s stock valued at $46,620,000 after purchasing an additional 109,405 shares during the last quarter. American Century Companies Inc. raised its holdings in Harmony Biosciences by 11.2% in the 3rd quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after acquiring an additional 168,145 shares during the last quarter. LSV Asset Management raised its holdings in Harmony Biosciences by 3.9% in the 4th quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock worth $62,008,000 after acquiring an additional 62,200 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Harmony Biosciences by 42.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock worth $35,701,000 after acquiring an additional 388,472 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Harmony Biosciences by 4,102.4% in the 4th quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after acquiring an additional 938,783 shares during the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Weiss Ratings lowered shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Truist Financial boosted their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. UBS Group decreased their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Finally, Needham & Company LLC decreased their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Price Performance

Shares of HRMY opened at $30.76 on Thursday. The firm has a market cap of $1.78 billion, a PE ratio of 12.40, a P/E/G ratio of 0.21 and a beta of 0.97. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The firm has a fifty day simple moving average of $29.58 and a two-hundred day simple moving average of $33.18. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. Harmony Biosciences’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.78 earnings per share. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.